KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Assets (2017 - 2025)

Moderna (MRNA) has disclosed Assets for 9 consecutive years, with $12.3 billion as the latest value for Q4 2025.

  • Quarterly Assets fell 12.76% to $12.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.3 billion through Dec 2025, down 12.76% year-over-year, with the annual reading at $12.3 billion for FY2025, 12.76% down from the prior year.
  • Assets for Q4 2025 was $12.3 billion at Moderna, up from $12.1 billion in the prior quarter.
  • The five-year high for Assets was $27.6 billion in Q1 2022, with the low at $12.0 billion in Q2 2025.
  • Average Assets over 5 years is $18.8 billion, with a median of $17.6 billion recorded in 2023.
  • The sharpest move saw Assets surged 513.97% in 2021, then crashed 30.66% in 2024.
  • Over 5 years, Assets stood at $24.7 billion in 2021, then increased by 4.82% to $25.9 billion in 2022, then dropped by 28.74% to $18.4 billion in 2023, then decreased by 23.25% to $14.1 billion in 2024, then dropped by 12.76% to $12.3 billion in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $12.3 billion, $12.1 billion, and $12.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.